Scandion Oncology obtains EU Funding for SCO-101 in drug resistant breast cancer patients

Scandion Oncology A/S (”Scandion” or ”the Company”) announces today that the Company has obtained a SME Instrument phase I grant from EU.

The release as fetched from its publisher. scandiononcology.com ↗